Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma

NCT06910306 is registered in ClinicalTrials.gov with Alpha Tau Medical LTD. as lead sponsor.

NCT NCT06910306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06910306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma
Lead sponsor
Alpha Tau Medical LTD.
Phase
Not applicable
Overall status
Recruiting
Start date
October 1, 2025
Completion date
December 1, 2026
Enrollment
10 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma, recurrent gliomas